Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy
Braichotte, D. R.; Savary, J. F.; Monnier, P.; van den Bergh, H. E.
1996

Abstract

BACKGROUND AND OBJECTIVE: Under standardized conditions (drug and light dose, timing), the result of the photodynamic therapy (PDT) of carcinomas of the esophagus with tetra(meta-hydroxyphenyl)chlorin (mTHPC) shows large variations between patients. STUDY DESIGN/MATERIALS AND METHODS: Before patients underwent PDT treatment, the mTHPC level was measured in the lesion, the normal surrounding tissue, and the oral cavity, with an apparatus based on fluorescence spectroscopy. RESULTS: The fluctuations in degree of tumor destruction between patients can be explained by individual variations in the mTHPC level in the mucosa of the esophagus. The patients showing the highest mTHPC fluorescence signal had also the highest response to PDT. Also, a correlation between the mTHPC level in the oral cavity and esophagus mucosa has been found. CONCLUSION: PDT can be improved by measuring the mTHPC level in the esophagus or the oral cavity before treatment by fluorescence spectroscopy, and then by adjusting the light dose to be applied to the observed mTHPC level.

Details

Title Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy
Author(s) Braichotte, D. R. ; Savary, J. F. ; Monnier, P. ; van den Bergh, H. E.
Published in Lasers in Surgery and Medicine
Volume 19
Issue 3
Pages 340-346
Date 1996
ISSN 0196-8092
Keywords
Note MEDLINE
Copyright 2003 U.S. National Library of Medicine
Institute of Environmental Engineering, Ecole Polytechnique Federale, Lausanne, Switzerland
8007168
Journal; Article; (JOURNAL ARTICLE)
English
97082187
Human; Support, Non-U.S. Gov't
*Antineoplastic Agents: TU, therapeutic use; *Carcinoma, Squamous Cell: DT, drug therapy; *Esophageal Neoplasms: DT, drug therapy; *Mesoporphyrins: TU, therapeutic use; *Photochemotherapy; *Radiation-Sensitizing Agents: TU, therapeutic use; Radiometry: MT, methods; Spectrometry, Fluorescence; Triazenes: TU, therapeutic use
0 (Antineoplastic Agents); 0 (Mesoporphyrins); 0 (Radiation-Sensitizing Agents); 0 (Triazenes); 0 (temoporfin)
DOI https://doi.org/10.1002/(SICI)1096-9101(1996)19:3<340::AID-LSM10>3.0.CO;2-8
Other identifier(s) View record in Web of Science
Laboratories LPAS
Record Appears in Scientific production and competences > ENAC - School of Architecture, Civil and Environmental Engineering > ENAC Archives > LPAS - Air and Soil Pollution Laboratory
Peer-reviewed publications
Work produced at EPFL
Journal Articles
Published
Record creation date 2007-07-20

Actions